Evidence map›Paper›PMID 39594580›Full record

ArticleCells2024

Modifying the Glycocalyx of Melanoma Cells via Metabolic Glycoengineering Using

David Harris, Marcel Groß, Sebastian Staebler, Regina Ebert, Jürgen Seibel, Anja Katrin Boßerhoff

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

David HarrisInstitute of Biochemistry, Friedrich Alexander University Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany.
Marcel GroßInstitute of Organic Chemistry, Julius-Maximilians-University of Würzburg, Am Hubland, 97074 Würzburg, Germany.
Sebastian StaeblerInstitute of Biochemistry, Friedrich Alexander University Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany.ORCID 0000-0002-3772-477X
Regina EbertDepartment of Musculoskeletal Tissue Regeneration, Orthopedic Clinic König-Ludwig Haus, Julius-Maximilians-University of Würzburg, Friedrich-Bergius-Ring 15, 97076 Würzburg, Germany.ORCID 0000-0002-8192-869X
Jürgen SeibelInstitute of Organic Chemistry, Julius-Maximilians-University of Würzburg, Am Hubland, 97074 Würzburg, Germany.
Anja Katrin BoßerhoffInstitute of Biochemistry, Friedrich Alexander University Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany.ORCID 0000-0001-8147-394X

Funding

German Research Foundation Project number 326998133 - SFB/TRR 225 (Subprojects B05, C03)
6 · The paper itself

Abstract

Tumor cells are decorated with aberrant glycan structures on cell surfaces. It is well known that the glycocalyx serves as a main cellular regulator, although its role in cancer is still not completely understood. Over recent decades, several non-natural monosaccharides carrying clickable groups have been introduced in melanoma cells. This technique, called Metabolic Glycoengineering (MGE), opens up the possibility of altering the cell's glycocalyx via click chemistry using a two-step approach. This study expands the field of MGE by showing the successful metabolic incorporation of novel alternative artificial glucosamine derivatives. The latter were either deoxygenated or blocked by methyl ether in position 4 to generate deficient glycosylation patterns, while being extended by an alkyne to enable click chemistry as a one-step approach. As a result, we observed a reduced proliferation rate of melanoma cells. Furthermore, using a lectin array, the decrease in high mannose epitopes was observed. In summary, the successful use of alternative artificial glucosamine derivatives enabled a significant alteration in the glycocalyx, consequently influencing cell behavior.

Indexed as

AcetylglucosamineGlycocalyxMelanomaCell Line, TumorCell ProliferationClick ChemistryGlycosylationHumansMannoseMetabolic EngineeringAcetylglucosamineMannoseclick chemistryglycoproteinsmelanoma cellsmetabolic glycoengineering

Identifiers

PMID39594580
PMCPMC11592549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.